These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 22043041)

  • 1. Strategies to translate preclinical information to breast cancer patient benefit.
    Daidone MG; Zaffaroni N; Cappelletti V
    J Natl Cancer Inst Monogr; 2011; 2011(43):55-9. PubMed ID: 22043041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bridging the gap between translational research and clinical application.
    Miller WR; Larionov AA
    J Natl Cancer Inst Monogr; 2011; 2011(43):134-7. PubMed ID: 22043060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
    Generali D; Berruti A; Foroni C; Bazzola L; Andreis D; Allevi G; Bersiga A; Dogliotti L; Fox SB; Harris AL; Bottini A
    J Natl Cancer Inst Monogr; 2011; 2011(43):67-70. PubMed ID: 22043044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers predicting clinical benefit: fact or fiction?
    Guarneri V; Barbieri E; Conte P
    J Natl Cancer Inst Monogr; 2011; 2011(43):63-6. PubMed ID: 22043043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer.
    Nagasaki K; Miki Y
    Breast Cancer; 2008; 15(2):117-20. PubMed ID: 18274834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene profiling assay and application: the predictive role in primary therapy.
    Fumagalli D; Desmedt C; Ignatiadis M; Loi S; Piccart M; Sotiriou C
    J Natl Cancer Inst Monogr; 2011; 2011(43):124-7. PubMed ID: 22043058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixture classification model based on clinical markers for breast cancer prognosis.
    Zeng T; Liu J
    Artif Intell Med; 2010; 48(2-3):129-37. PubMed ID: 20005686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiles as an additional tool to conventional predictive factors to assist in management of early endocrine responsive breast cancer.
    Chow LW
    Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S13-7. PubMed ID: 20374025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
    Ross JS
    Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surrogate markers for targeted therapy-based treatment activity and efficacy.
    Bianchini G; Gianni L
    J Natl Cancer Inst Monogr; 2011; 2011(43):91-4. PubMed ID: 22043050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of prognostic profiling in breast cancer.
    Pusztai L
    Oncologist; 2008 Apr; 13(4):350-60. PubMed ID: 18448548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer.
    Generali D; Symmans WF; Berruti A; Fox SB
    J Natl Cancer Inst Monogr; 2011; 2011(43):99-102. PubMed ID: 22043052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The treatment of individual patients is more than a trial.
    Bottini A; Berruti A; Generali D; Dogliotti L
    J Natl Cancer Inst Monogr; 2011; 2011(43):53-4. PubMed ID: 22043040
    [No Abstract]   [Full Text] [Related]  

  • 16. New generation of molecular prognostic and predictive tests for breast cancer.
    Pusztai L; Cristofanilli M; Paik S
    Semin Oncol; 2007 Apr; 34(2 Suppl 3):S10-6. PubMed ID: 17512431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in breast cancer: overview.
    Arteaga CL
    Clin Cancer Res; 2013 Dec; 19(23):6353-9. PubMed ID: 24298065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
    Li X; Lewis MT; Huang J; Gutierrez C; Osborne CK; Wu MF; Hilsenbeck SG; Pavlick A; Zhang X; Chamness GC; Wong H; Rosen J; Chang JC
    J Natl Cancer Inst; 2008 May; 100(9):672-9. PubMed ID: 18445819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNAs in breast cancer pathogenesis.
    Götte M
    Minerva Ginecol; 2010 Dec; 62(6):559-71. PubMed ID: 21079577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive markers of response to neoadjuvant chemotherapy in breast cancer.
    Tewari M; Krishnamurthy A; Shukla HS
    Surg Oncol; 2008 Dec; 17(4):301-11. PubMed ID: 18467090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.